Iodinated Copper–Cysteamine Nanoparticles as Radiosensitizers for Tumor Radiotherapy
Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z eleme...
Saved in:
Published in | Pharmaceutics Vol. 17; no. 2; p. 149 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
22.01.2025
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131I-labeled Cu-Cy-I ([131I]Cu-Cy-I) nanoparticles. Methods: The synthesis of [131I]Cu-Cy-I nanoparticles was performed with [131I]I− anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [131I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results: The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice’s lives. Conclusions: Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [131I]Cu-Cy-I nanoparticles at a low 131I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [131I]Cu-Cy-I nanoparticles. |
---|---|
AbstractList | Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131I-labeled Cu-Cy-I ([131I]Cu-Cy-I) nanoparticles. Methods: The synthesis of [131I]Cu-Cy-I nanoparticles was performed with [131I]I− anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [131I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results: The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice’s lives. Conclusions: Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [131I]Cu-Cy-I nanoparticles at a low 131I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [131I]Cu-Cy-I nanoparticles. Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131I-labeled Cu-Cy-I ([131I]Cu-Cy-I) nanoparticles. Methods: The synthesis of [131I]Cu-Cy-I nanoparticles was performed with [131I]I- anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [131I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results: The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice's lives. Conclusions: Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [131I]Cu-Cy-I nanoparticles at a low 131I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [131I]Cu-Cy-I nanoparticles.Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131I-labeled Cu-Cy-I ([131I]Cu-Cy-I) nanoparticles. Methods: The synthesis of [131I]Cu-Cy-I nanoparticles was performed with [131I]I- anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [131I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results: The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice's lives. Conclusions: Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [131I]Cu-Cy-I nanoparticles at a low 131I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [131I]Cu-Cy-I nanoparticles. Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of I-labeled Cu-Cy-I ([ I]Cu-Cy-I) nanoparticles. : The synthesis of [ I]Cu-Cy-I nanoparticles was performed with [ I]I anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [ I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. : The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice's lives. : Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [ I]Cu-Cy-I nanoparticles at a low I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [ I]Cu-Cy-I nanoparticles. Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131 I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131 I-labeled Cu-Cy-I ([ 131 I]Cu-Cy-I) nanoparticles. Methods : The synthesis of [ 131 I]Cu-Cy-I nanoparticles was performed with [ 131 I]I − anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [ 131 I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results : The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice’s lives. Conclusions : Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [ 131 I]Cu-Cy-I nanoparticles at a low 131 I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [ 131 I]Cu-Cy-I nanoparticles. |
Author | Xu, Ying Li, Shihong Zhang, Miaomiao Yang, Yu Wang, Jie |
AuthorAffiliation | 3 Institute for Advanced Materials, School of Material Science and Engineering, Jiangsu University, Zhenjiang 212013, China; wangjie@ujs.edu.cn 2 Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China 1 State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Suzhou Medical College of Soochow University, Suzhou 215123, China; 20224220061@stu.suda.edu.cn (M.Z.); yangyu6335@126.com (Y.Y.); 20224020015@stu.suda.edu.cn (Y.X.) |
AuthorAffiliation_xml | – name: 3 Institute for Advanced Materials, School of Material Science and Engineering, Jiangsu University, Zhenjiang 212013, China; wangjie@ujs.edu.cn – name: 1 State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Suzhou Medical College of Soochow University, Suzhou 215123, China; 20224220061@stu.suda.edu.cn (M.Z.); yangyu6335@126.com (Y.Y.); 20224020015@stu.suda.edu.cn (Y.X.) – name: 2 Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China |
Author_xml | – sequence: 1 givenname: Miaomiao surname: Zhang fullname: Zhang, Miaomiao – sequence: 2 givenname: Yu surname: Yang fullname: Yang, Yu – sequence: 3 givenname: Ying surname: Xu fullname: Xu, Ying – sequence: 4 givenname: Jie orcidid: 0000-0003-3150-6947 surname: Wang fullname: Wang, Jie – sequence: 5 givenname: Shihong orcidid: 0000-0003-4047-2988 surname: Li fullname: Li, Shihong |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40006516$$D View this record in MEDLINE/PubMed |
BookMark | eNptks1u1DAQgCNUREvpI4AiceGyYGecxD4htOJnpQokVLhaY3vc9WoTBztBWk68A2_Ik5DuLlWL8MEeez59HtnzuDjpY09F8ZSzlwCKvRrWmDq0NI3BZt6yinGhHhRnXCm1EKqCkzvxaXGR84bNA4BLUI-KUzFvmpo3Z8XXVXShx5FcuYzDQOn3z1_LXR4Ju9BT-RH7OGCar9lSLjGXn9GFmKnPYQw_KOXSx1ReTd0871PjmhIOuyfFQ4_bTBfH9bz48u7t1fLD4vLT-9XyzeXCilqMi5Yx6blyQrS28pXzigRDqWytRM2kZYitawSDRtUGBYC10JBRSBy8QYTzYnXwuogbPaTQYdrpiEHvD2K61sfqNTMADDwwZ5ww5I2S6Ik55701poLZ9frgGibTkbPUjwm396T3M31Y6-v4XXMua6kqNRteHA0pfpsoj7oL2dJ2iz3FKWvgLQfJZVvP6PN_0E2cUj-_1Z7irWzhRvjsbkm3tfz9vxmoD4BNMedE_hbhTN-0iv5vq8AfXF64Yg |
Cites_doi | 10.1039/D3CC01355C 10.1007/s11307-011-0489-z 10.1186/s13046-018-0758-7 10.3389/fbioe.2022.920162 10.1016/j.pdpdt.2023.103816 10.1038/s41571-022-00697-z 10.1002/adhm.202000802 10.1039/C9CP04392F 10.1016/j.msec.2020.110659 10.1038/s41598-017-09375-y 10.1002/anie.202107231 10.1016/j.bbcan.2019.07.003 10.1021/acsnano.3c05853 10.1016/S2214-109X(24)00355-3 10.1111/j.1751-1097.2009.00558.x 10.1038/nnano.2015.17 10.1039/C9TB01566C 10.1088/0031-9155/41/10/004 10.2147/IJN.S362759 10.1007/978-1-60761-411-1_4 10.1088/0031-9155/60/17/6701 10.1002/adma.201904894 10.1038/s41392-020-0156-4 10.1517/17425247.2016.1167035 10.1166/jbn.2014.1954 10.1021/acs.bioconjchem.4c00334 10.1021/jp4077189 10.3390/radiation1010002 10.1016/j.mtphys.2021.100435 10.7150/thno.75279 10.1039/c8pp00112j 10.1016/j.addr.2017.01.004 10.1021/acsnano.3c00891 10.1039/C4TC00114A 10.1007/978-3-031-04071-9 10.3390/nano10061087 10.1038/nnano.2011.166 |
ContentType | Journal Article |
Copyright | 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2025 by the authors. 2025 |
Copyright_xml | – notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2025 by the authors. 2025 |
DBID | AAYXX CITATION NPM 3V. 7XB 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO GNUQQ GUQSH M2O MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
DOI | 10.3390/pharmaceutics17020149 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea ProQuest Central Student Research Library Prep Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic CrossRef PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1999-4923 |
ExternalDocumentID | oai_doaj_org_article_0b3303f30dbd4befb98afe0ddffcbb23 PMC11858929 40006516 10_3390_pharmaceutics17020149 |
Genre | Journal Article |
GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 12175163 |
GroupedDBID | --- 53G 5VS 8G5 AADQD AAYXX ABDBF ABUWG ACGFO ACIHN ACUHS AEAQA AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AZQEC BENPR BPHCQ CCPQU CITATION DIK DWQXO EBD ESX F5P FD6 GNUQQ GROUPED_DOAJ GUQSH GX1 HH5 HYE IAO IHR ITC KQ8 M2O M48 MK0 MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM TR2 TUS 3V. NPM 7XB 8FK MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c454t-7008f19d447c2f2df9e40a89c594508c0aa7d6403695ba433cc36eb9ae13fbaa3 |
IEDL.DBID | M48 |
ISSN | 1999-4923 |
IngestDate | Wed Aug 27 01:32:44 EDT 2025 Thu Aug 21 18:27:43 EDT 2025 Thu Jul 10 22:05:40 EDT 2025 Mon Jun 30 12:12:35 EDT 2025 Sat Mar 01 01:25:39 EST 2025 Tue Jul 01 00:37:20 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | radiotherapy X-ray-induced photodynamic therapy copper–cysteamine nanoparticles 131I radiosensitization |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c454t-7008f19d447c2f2df9e40a89c594508c0aa7d6403695ba433cc36eb9ae13fbaa3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-4047-2988 0000-0003-3150-6947 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/pharmaceutics17020149 |
PMID | 40006516 |
PQID | 3171178739 |
PQPubID | 2032349 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_0b3303f30dbd4befb98afe0ddffcbb23 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11858929 proquest_miscellaneous_3171381875 proquest_journals_3171178739 pubmed_primary_40006516 crossref_primary_10_3390_pharmaceutics17020149 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20250122 |
PublicationDateYYYYMMDD | 2025-01-22 |
PublicationDate_xml | – month: 1 year: 2025 text: 20250122 day: 22 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Pharmaceutics |
PublicationTitleAlternate | Pharmaceutics |
PublicationYear | 2025 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Larue (ref_11) 2018; 17 Guo (ref_19) 2021; 60 Ma (ref_28) 2014; 2 Eruslanov (ref_31) 2010; 594 Yu (ref_14) 2019; 31 Glaser (ref_17) 2015; 60 Ran (ref_16) 2012; 14 ref_34 Tang (ref_20) 2018; 37 Daouk (ref_12) 2020; 1 Liu (ref_18) 2022; 12 Cabral (ref_37) 2011; 6 Emfietzoglou (ref_33) 2005; 46 ref_39 Zhu (ref_1) 2024; 12 Xu (ref_38) 2023; 17 Bulin (ref_10) 2013; 117 Zhang (ref_29) 2020; 5 Allen (ref_3) 2017; 109 Xiong (ref_7) 2024; 35 Goins (ref_35) 2016; 13 Overchuk (ref_8) 2023; 17 Rodriguez (ref_32) 2009; 85 ref_25 Wang (ref_27) 2021; 19 Vozenin (ref_2) 2022; 12 ref_24 ref_21 Kotagiri (ref_13) 2015; 10 Lioret (ref_15) 2023; 44 Wang (ref_9) 2021; 10 Ye (ref_5) 2022; 17 Zweit (ref_36) 1996; 41 Ma (ref_22) 2014; 10 Wei (ref_4) 2023; 59 ref_26 Alias (ref_30) 2019; 21 Pandey (ref_23) 2019; 7 ref_6 |
References_xml | – volume: 59 start-page: 6956 year: 2023 ident: ref_4 article-title: Recent progress in metal complexes functionalized nanomaterials for photodynamic therapy publication-title: Chem. Commun. doi: 10.1039/D3CC01355C – volume: 14 start-page: 156 year: 2012 ident: ref_16 article-title: In vivo photoactivation without “light”: Use of Cherenkov radiation to overcome the penetration limit of light publication-title: Mol. Imaging Biol. doi: 10.1007/s11307-011-0489-z – volume: 37 start-page: 87 year: 2018 ident: ref_20 article-title: Role of metabolism in cancer cell radioresistance and radiosensitization methods publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-018-0758-7 – ident: ref_6 doi: 10.3389/fbioe.2022.920162 – volume: 44 start-page: 103816 year: 2023 ident: ref_15 article-title: Cherenkov Radiation induced photodynamic therapy—Repurposing older photosensitizers, and radionuclides publication-title: Photodiagn. Photodyn. Ther. doi: 10.1016/j.pdpdt.2023.103816 – ident: ref_34 – volume: 12 start-page: 791 year: 2022 ident: ref_2 article-title: Towards clinical translation of FLASH radiotherapy publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-022-00697-z – volume: 10 start-page: e2000802 year: 2021 ident: ref_9 article-title: Radioiodinated Persistent Luminescence Nanoplatform for Radiation-Induced Photodynamic Therapy and Radiotherapy publication-title: Adv. Healthc. Mater. doi: 10.1002/adhm.202000802 – volume: 21 start-page: 21084 year: 2019 ident: ref_30 article-title: Theoretical studies on the energy structures and optical properties of copper cysteamine—A novel sensitizer publication-title: Phys. Chem. Chem. Phys. doi: 10.1039/C9CP04392F – ident: ref_24 doi: 10.1016/j.msec.2020.110659 – ident: ref_26 doi: 10.1038/s41598-017-09375-y – volume: 60 start-page: 21884 year: 2021 ident: ref_19 article-title: Smart 131 I-Labeled Self-Illuminating Photosensitizers for Deep Tumor Therapy publication-title: Angew. Chem. Int. Ed. Engl. doi: 10.1002/anie.202107231 – ident: ref_39 doi: 10.1016/j.bbcan.2019.07.003 – volume: 17 start-page: 20825 year: 2023 ident: ref_38 article-title: Size-Dependent In Vivo Transport of Nanoparticles: Implications for Delivery, Targeting, and Clearance publication-title: ACS Nano doi: 10.1021/acsnano.3c05853 – volume: 12 start-page: e1945 year: 2024 ident: ref_1 article-title: Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: A population-based study publication-title: Lancet Glob. Health doi: 10.1016/S2214-109X(24)00355-3 – volume: 85 start-page: 1189 year: 2009 ident: ref_32 article-title: Structural factors and mechanisms underlying the improved photodynamic cell killing with silicon phthalocyanine photosensitizers directed to lysosomes versus mitochondria publication-title: Photochem. Photobiol. doi: 10.1111/j.1751-1097.2009.00558.x – volume: 10 start-page: 370 year: 2015 ident: ref_13 article-title: Breaking the depth dependency of phototherapy with Cerenkov radiation and low-radiance-responsive nanophotosensitizers publication-title: Nat. Nanotechnol. doi: 10.1038/nnano.2015.17 – volume: 7 start-page: 6630 year: 2019 ident: ref_23 article-title: A facile method for the synthesis of copper-cysteamine nanoparticles and study of ROS production for cancer treatment publication-title: J. Mater. Chem. B doi: 10.1039/C9TB01566C – volume: 41 start-page: 1905 year: 1996 ident: ref_36 article-title: Radionuclides and carrier molecules for therapy publication-title: Phys. Med. Biol. doi: 10.1088/0031-9155/41/10/004 – volume: 17 start-page: 2367 year: 2022 ident: ref_5 article-title: Recent Progress of Metal-Organic Framework-Based Photodynamic Therapy for Cancer Treatment publication-title: Int. J. Nanomed. doi: 10.2147/IJN.S362759 – volume: 594 start-page: 57 year: 2010 ident: ref_31 article-title: Identification of ROS using oxidized DCFDA and flow-cytometry publication-title: Methods Mol. Biol. doi: 10.1007/978-1-60761-411-1_4 – volume: 60 start-page: 6701 year: 2015 ident: ref_17 article-title: Cherenkov radiation fluence estimates in tissue for molecular imaging and therapy applications publication-title: Phys. Med. Biol. doi: 10.1088/0031-9155/60/17/6701 – volume: 46 start-page: 89 year: 2005 ident: ref_33 article-title: Liposome-mediated radiotherapeutics within avascular tumor spheroids: Comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody publication-title: J. Nucl. Med. – volume: 31 start-page: e1904894 year: 2019 ident: ref_14 article-title: A “Missile-Detonation” Strategy to Precisely Supply and Efficiently Amplify Cerenkov Radiation Energy for Cancer Theranostics publication-title: Adv. Mater. doi: 10.1002/adma.201904894 – volume: 5 start-page: 58 year: 2020 ident: ref_29 article-title: Use of copper-cysteamine nanoparticles to simultaneously enable radiotherapy, oxidative therapy and immunotherapy for melanoma treatment publication-title: Signal Transduct. Target. Ther. doi: 10.1038/s41392-020-0156-4 – volume: 13 start-page: 873 year: 2016 ident: ref_35 article-title: Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy publication-title: Expert Opin. Drug Deliv. doi: 10.1517/17425247.2016.1167035 – volume: 10 start-page: 1501 year: 2014 ident: ref_22 article-title: A new X-ray activated nanoparticle photosensitizer for cancer treatment publication-title: J. Biomed. Nanotechnol. doi: 10.1166/jbn.2014.1954 – volume: 35 start-page: 1269 year: 2024 ident: ref_7 article-title: Development of a Self-Luminescent Living Bioreactor for Enhancing Photodynamic Therapy in Breast Cancer publication-title: Bioconjug. Chem. doi: 10.1021/acs.bioconjchem.4c00334 – volume: 117 start-page: 21583 year: 2013 ident: ref_10 article-title: X-ray-Induced Singlet Oxygen Activation with Nanoscintillator-Coupled Porphyrins publication-title: J. Phys. Chem. C doi: 10.1021/jp4077189 – volume: 1 start-page: 5 year: 2020 ident: ref_12 article-title: Can Cerenkov Light Really Induce an Effective Photodynamic Therapy? publication-title: Radiation doi: 10.3390/radiation1010002 – volume: 19 start-page: 100435 year: 2021 ident: ref_27 article-title: A new type of cuprous-cysteamine sensitizers: Synthesis, optical properties and potential applications publication-title: Mater. Today Phys. doi: 10.1016/j.mtphys.2021.100435 – volume: 12 start-page: 7404 year: 2022 ident: ref_18 article-title: Cerenkov radiation-activated probes for deep cancer theranostics: A review publication-title: Theranostics doi: 10.7150/thno.75279 – volume: 17 start-page: 1612 year: 2018 ident: ref_11 article-title: Using X-rays in photodynamic therapy: An overview publication-title: Photochem. Photobiol. Sci. doi: 10.1039/c8pp00112j – volume: 109 start-page: 1 year: 2017 ident: ref_3 article-title: Radiotherapy for Cancer: Present and Future publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2017.01.004 – volume: 17 start-page: 7979 year: 2023 ident: ref_8 article-title: Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine publication-title: ACS Nano doi: 10.1021/acsnano.3c00891 – volume: 2 start-page: 4239 year: 2014 ident: ref_28 article-title: A new Cu–cysteamine complex: Structure and optical properties publication-title: J. Mater. Chem. C doi: 10.1039/C4TC00114A – ident: ref_21 doi: 10.1007/978-3-031-04071-9 – ident: ref_25 doi: 10.3390/nano10061087 – volume: 6 start-page: 815 year: 2011 ident: ref_37 article-title: Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size publication-title: Nat. Nanotechnol. doi: 10.1038/nnano.2011.166 |
SSID | ssj0000331839 |
Score | 2.3426983 |
Snippet | Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a... Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a new type of... Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a... Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 149 |
SubjectTerms | 131I Biotechnology Cancer therapies Copper copper–cysteamine nanoparticles Light Nanoparticles Ovarian cancer Photodynamic therapy Polyvinyl alcohol Radiation therapy Radioactivity radiosensitization radiotherapy Reactive oxygen species Tumors X-ray-induced photodynamic therapy |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYQp14QUB4ptDIS4kRKHDsPH9tVEa0EQmipuEXjl9gDyYrsHpYT_4F_2F_ScRz2USH1wiWH2FIcz9jzfcnMZ0KONeMI8zUuJFHyWHjxWSiSLM6VcTwDzyh87fDlVX5xK37dZXdLR335nLAgDxwm7ixRyLi544lRRijrlCzB2cQY57RSaafziTFviUx1ezD3vipDyQ5HXn82vl98Im5ZgSiJef3MpWDUafa_BTT_zZdcCkDnm2SjR470WxjxFlmz9TY5uQ4PnJ3S4aKSqj2lJ_R6IUo9-0h-_2wwSiGwNHTQjMf28c_zy8CrOMMD4kyKmyyy5z5JjkJLb8CMmtZnt09GTwgRKYJbOpw-4LVrCnVbsx1ye_5jOLiI-zMVYi0yMYkLjPmOSSNEoVOXGietSKCUOpMCsZpOAAqTC4xrMlMgONea51ZJsIw7BcB3yXrd1HafUOaQy4GSNle50IkuNfdyckxZAC8uGpGvr5NbjYN0RoWUw1ujetMaEfnuTTDv7JWvuxvoD1U_BdX__CEih68GrPrl2FYIkhjDrYnjM47mzbiQ_N8RqG0zDX08fCmyiOwFe89HIjqoxvKIlCuesDLU1ZZ6dN-JdSOBy0rEoJ_e4-UOyIfUnz-csDhND8n65HFqPyMomqgvnf__Bft9EwY priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7B9sIF8SZQkJFQTw2NY-fhE6KrVgWJalVtUW-Rn3QPTcJm97Cc-A_8Q34J48S720UVlxxiS7Ey45lv7JlvAN5ryhDma9xIvGQx9-SzskiyOFfGsUz6iMLXDn89z88u-Zer7CocuHUhrXJtE3tDbRrtz8iP0M9RitrFxMf2R-y7Rvnb1dBC4z7soQkuyxHsHZ-cTy42pywJ8zorhtIdhvH9UXu9PSruaIFoiXoezVtOqefuvwtw_ps3ecsRnT6ChwFBkk-DyB_DPVs_gYPJ8MHVIZluK6q6Q3JAJlty6tVT-Pa5QW-FANOQcdO2dv7n1--xZ3OWN4g3CRpbjKJDshyRHbmQZtZ0Pst9MfuJUJEgyCXT5Q0--6Ghfmv1DC5PT6bjszj0Vog1z_giLtD3OyoM54VOXWqcsDyRpdCZ4IjZdCJlYXKO_k1kSnLGtGa5VUJaypySkj2HUd3U9iUQ6jCmk0rYXOVcJ7rUzNPKUWWl9CSjEXxY_9yqHSg0Kgw9vDSqO6URwbEXwWayZ8DuXzTz71X4BVWiGHpfxxKjDFfWKVFKZxNjnNNKpSyC_bUAq7Atu2qrRBG82wzjhvK3JLK2zXKY42FMkUXwYpD3ZiW8h2w0j6Dc0YSdpe6O1LPrnrQbA7msRCz66v_reg0PUt9hOKFxmu7DaDFf2jcIexbqbdDtvwK5CWY priority: 102 providerName: ProQuest |
Title | Iodinated Copper–Cysteamine Nanoparticles as Radiosensitizers for Tumor Radiotherapy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40006516 https://www.proquest.com/docview/3171178739 https://www.proquest.com/docview/3171381875 https://pubmed.ncbi.nlm.nih.gov/PMC11858929 https://doaj.org/article/0b3303f30dbd4befb98afe0ddffcbb23 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ3fa9swEMePrn3Zy-h-u-2CBqNPdWdZ8g89lLKGlm7QEkoCfTP6uQZWO40TWPbX72Q7yTIy2EseImMZ3Un3OVv6HsAnTRlivsaJxHMWci8-K7MoCVNlHEukzyj82eGb2_R6xL_dJ_c7sBRU6Aaw3pra-XpSo-mP059Pi3Oc8Gc-48SU_fPkYf32t6YZAhBi_zPYw-CU-aIGNx3xN4sz804smm_NwtdXi1l7ruffd9qIWI2w_zYa_XtT5R9R6mofXnR4Sb60_vASdmz5Co4HbYeLEzJcH7eqT8gxGayVqxevYfi1wlCG9GlIv5pM7DTse6Fn-YgoSnAdxgS720dHZE3upBlXtd8APxv_QookyL9kOH_E36apPdq1eAOjq8th_zrsyi6Emid8FmaIBY4Kw3mmYxcbJyyPZC50IjjinI6kzEzKMfSJREnOmNYstUpIS5lTUrK3sFtWpX0PhDpM96QSNlUp15HONfOKc1RZKb3-aACny6EtJq26RoFZibdFsdUWAVx4A6wu9uLYzR_V9HvRDUERKYaB2bHIKMOVdUrk0tnIGOe0UjEL4GhpvmLpcAVyFKW4ejHs4-OqGeea_4AiS1vN22s84WRJAO9aa6-ehDc0R9MA8g0_2HjUzZZy_NDoeWOOl-SIqQf_0fEhPI99BeKIhnF8BLuz6dx-QCyaqR7sXVzeDu56zWuFXuP2vwHdhxMZ |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEB6V9AAXxD-GAosEPdXU613_HRCioVVC2yiqUtSbu780h8YhToTCiXfgPXgonoRZ20kaVHHrxQfvyl7vzM58s975BuCNogxhvsKFxFPmc0c-K5Ig8mOpLYuEiyhc7vBxL-6c8s9n0dkG_F7kwrhjlQubWBlqXSi3R76Lfo5S1C6WfRh_813VKPd3dVFCo1aLQzP_jiFb-b77CeX7NgwP9gftjt9UFfAVj_jUT9DrWZppzhMV2lDbzPBApJmKMo5oRQVCJDrmaNmzSArOmFIsNjIThjIrhWD43FuwyfEbwxZs7u33-ifLXZ2AuTWS1alCjGXB7vhitTVd0gTRGXW8nVecYFUr4DqA--85zSuO7-Ae3G0QK_lYq9h92DCjB7Ddr1843yGDVQZXuUO2SX9Fhj1_CF-6BXpHBLSatIvx2Ez-_PzVduzR4hLxLUHjjlF7cziPiJKcCD0sSneqfjr8gdCUIKgmg9klXqumOl9s_ghOb2TWH0NrVIzMUyDUYgwpZGZiGXMVqFQxR2NHpRHCkZp68G4xufm4puzIMdRx0sivlYYHe04Ey86Ocbu6UUy-5s0U5IFk6O0tC7TUXBors1RYE2htrZIyZB5sLQSYN2agzFdK68HrZTMuYPdXRoxMMav7ONiURB48qeW9HAmvICKNPUjXNGFtqOsto-FFRRKOgWOUIvZ99v9xvYLbncHxUX7U7R0-hzuhq24cUD8Mt6A1nczMC4RcU_my0XMC5ze9tP4CakhGYQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVEJcEG8MBRYJeqqJ17t-HRCiaaOGQhRVKerN7JPm0DjEiVA48R_4N_wcfgmztpM0qOLWSw5ZK1ntvL5Zz3wD8EpRhjBfoSHxlPnckc-KJIj8WGrLIuEyCtc7_KkfH53yD2fR2Rb8XvbCuLLKpU-sHLUulLsjb2OcoxS1i2Vt25RFDA667ybffDdByr1pXY7TqFXk2Cy-Y_pWvu0doKxfh2H3cNg58psJA77iEZ_5CUZASzPNeaJCG2qbGR6INFNRxhG5qECIRMccvXwWScEZU4rFRmbCUGalEAx_9wZsJy4rasH2_mF_cLK64QmYs5esbhtiLAvak_P1NXVJE0Rq1HF4XgqI1dyAq8DuvzWbl4Jg9w7cbtAreV-r213YMuN7sDuo_3CxR4brbq5yj-ySwZoYe3EfPvcKjJQIbjXpFJOJmf75-avjmKTFBWJdgo4eM_imUI-IkpwIPSpKV2E_G_1AmEoQYJPh_AI_q6W6d2zxAE6v5dQfQmtcjM1jINRiPilkZmIZcxWoVDFHaUelEcIRnHrwZnm4-aSm78gx7XHSyK-Uhgf7TgSrhx37dvVFMf2aN0eQB5Jh5Lcs0FJzaazMUmFNoLW1SsqQebCzFGDeuIQyXyuwBy9Xy2jM7g2NGJtiXj_jIFQSefColvdqJ7yCizT2IN3QhI2tbq6MR-cVYTgmkVGKOPjJ__f1Am6iSeUfe_3jp3ArdIOOA-qH4Q60ZtO5eYboayafN2pO4Mt1W9ZfHU5Klg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Iodinated+Copper-Cysteamine+Nanoparticles+as+Radiosensitizers+for+Tumor+Radiotherapy&rft.jtitle=Pharmaceutics&rft.au=Zhang%2C+Miaomiao&rft.au=Yang%2C+Yu&rft.au=Xu%2C+Ying&rft.au=Wang%2C+Jie&rft.date=2025-01-22&rft.issn=1999-4923&rft.eissn=1999-4923&rft.volume=17&rft.issue=2&rft_id=info:doi/10.3390%2Fpharmaceutics17020149&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon |